PortfoliosLab logo
PortfoliosLab logo
Tools
Performance Analysis
Portfolio Analysis
Factor Model
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
PACB vs. CRSP
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Correlation

The correlation between PACB and CRSP is 0.42, which is considered to be moderate. This suggests that the two assets have some degree of positive relationship in their price movements. Moderate correlation can be acceptable for portfolio diversification, offering a balance between risk and potential returns.


-0.50.00.51.00.4

Performance

PACB vs. CRSP - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Pacific Biosciences of California, Inc. (PACB) and CRISPR Therapeutics AG (CRSP). The values are adjusted to include any dividend payments, if applicable.

-100.00%0.00%100.00%200.00%300.00%JulyAugustSeptemberOctoberNovemberDecember
-77.23%
189.00%
PACB
CRSP

Key characteristics

Sharpe Ratio

PACB:

-0.68

CRSP:

-0.66

Sortino Ratio

PACB:

-0.98

CRSP:

-0.80

Omega Ratio

PACB:

0.88

CRSP:

0.91

Calmar Ratio

PACB:

-0.82

CRSP:

-0.41

Martin Ratio

PACB:

-1.08

CRSP:

-0.91

Ulcer Index

PACB:

73.88%

CRSP:

36.17%

Daily Std Dev

PACB:

117.89%

CRSP:

50.33%

Max Drawdown

PACB:

-97.65%

CRSP:

-81.61%

Current Drawdown

PACB:

-96.15%

CRSP:

-80.61%

Fundamentals

Market Cap

PACB:

$579.80M

CRSP:

$3.78B

EPS

PACB:

-$1.46

CRSP:

-$2.79

PEG Ratio

PACB:

-0.17

CRSP:

-0.21

Total Revenue (TTM)

PACB:

$173.15M

CRSP:

$201.62M

Gross Profit (TTM)

PACB:

$31.38M

CRSP:

$61.70M

EBITDA (TTM)

PACB:

-$320.47M

CRSP:

-$313.08M

Returns By Period

In the year-to-date period, PACB achieves a -79.92% return, which is significantly lower than CRSP's -34.95% return.


PACB

YTD

-79.92%

1M

14.53%

6M

34.01%

1Y

-80.10%

5Y*

-17.95%

10Y*

-12.48%

CRSP

YTD

-34.95%

1M

-13.84%

6M

-27.60%

1Y

-32.81%

5Y*

-9.78%

10Y*

N/A

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Risk-Adjusted Performance

PACB vs. CRSP - Risk-Adjusted Performance Comparison

This table presents a comparison of risk-adjusted performance metrics for Pacific Biosciences of California, Inc. (PACB) and CRISPR Therapeutics AG (CRSP). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


Sharpe ratio
The chart of Sharpe ratio for PACB, currently valued at -0.68, compared to the broader market-4.00-2.000.002.00-0.68-0.66
The chart of Sortino ratio for PACB, currently valued at -0.98, compared to the broader market-4.00-2.000.002.004.00-0.98-0.80
The chart of Omega ratio for PACB, currently valued at 0.88, compared to the broader market0.501.001.502.000.880.91
The chart of Calmar ratio for PACB, currently valued at -0.82, compared to the broader market0.002.004.006.00-0.82-0.41
The chart of Martin ratio for PACB, currently valued at -1.08, compared to the broader market-5.000.005.0010.0015.0020.0025.00-1.08-0.91
PACB
CRSP

The current PACB Sharpe Ratio is -0.68, which is comparable to the CRSP Sharpe Ratio of -0.66. The chart below compares the historical Sharpe Ratios of PACB and CRSP, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.


Rolling 12-month Sharpe Ratio-1.00-0.500.000.50JulyAugustSeptemberOctoberNovemberDecember
-0.68
-0.66
PACB
CRSP

Dividends

PACB vs. CRSP - Dividend Comparison

Neither PACB nor CRSP has paid dividends to shareholders.


Tickers have no history of dividend payments

Drawdowns

PACB vs. CRSP - Drawdown Comparison

The maximum PACB drawdown since its inception was -97.65%, which is greater than CRSP's maximum drawdown of -81.61%. Use the drawdown chart below to compare losses from any high point for PACB and CRSP. For additional features, visit the drawdowns tool.


-95.00%-90.00%-85.00%-80.00%-75.00%-70.00%JulyAugustSeptemberOctoberNovemberDecember
-96.15%
-80.61%
PACB
CRSP

Volatility

PACB vs. CRSP - Volatility Comparison

Pacific Biosciences of California, Inc. (PACB) has a higher volatility of 26.23% compared to CRISPR Therapeutics AG (CRSP) at 19.01%. This indicates that PACB's price experiences larger fluctuations and is considered to be riskier than CRSP based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


10.00%20.00%30.00%40.00%50.00%JulyAugustSeptemberOctoberNovemberDecember
26.23%
19.01%
PACB
CRSP

Financials

PACB vs. CRSP - Financials Comparison

This section allows you to compare key financial metrics between Pacific Biosciences of California, Inc. and CRISPR Therapeutics AG. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


Values in USD except per share items
PortfoliosLab logo
Performance Analysis
Portfolio AnalysisPortfolio PerformanceStock ComparisonSharpe RatioMartin RatioTreynor RatioSortino RatioOmega RatioCalmar RatioSummers Ratio
Community
Discussions


Disclaimer

The information contained herein does not constitute investment advice and made available for educational purposes only. Prices and returns on equities are listed without consideration of fees, commissions, taxes, penalties, or interest payable due to purchasing, holding, or selling.

Copyright © 2024 PortfoliosLab